{"entity":{"id":"nct05749588","kind":"trial","name":"FUSCC Refractory TNBC Platform Study (FUTURE2.0)","aka":[],"tldr":"A phase 2 trial of camrelizumab, everolimus, TQB2102 and TQB2868 in triple-negative breast cancer, run by Fudan University, now recruiting.","summary":"FUSCC Refractory TNBC Platform Study (FUTURE2.0) is a phase 2, interventional study registered as NCT05749588 by Fudan University, with a registry enrolment figure of 120 participants, started 2023-03-30 and due to reach its primary completion in 2027-12-31. Interventions recorded: A1: SHR-A1811; A2: SHR-A1811 with Camrelizumab with famitinib; B1: TROP2 ADC; B2: TROP2 ADC with Camrelizumab; C1: SHR-A1811; C2: SHR-A1811 with BP102; D1: TROP2 ADC; D2: TROP2 ADC with BP102; E1: SHR-A1811; F1: TROP2 ADC; G1: SHR-A1811; H1: TROP2 ADC; E2: SHR-A1811 with everolimus; TQB2102 with TQB2868. Conditions listed: Triple-negative Breast Cancer. Triple-negative eligibility wording from the registry: \"TNBC invasive breast cancer confirmed by histology (specific definition: ER \\<1% positive tumor cells by immunohistochemistry are defined as ER negative, PR \\<1% positive tumor cells are defined as PR negative, HER2 0-1+ or HER2 ++ but negative by FISH without amplification was defined as HER2 negat\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT05749588","url":"https://clinicaltrials.gov/study/NCT05749588"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-metastatic"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["camrelizumab","everolimus","tqb2102","tqb2868"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05749588","phase":"2","setting":"Precision Platform Study of Refractory Triple-negative Breast Cancer Based on Molecular Subtyping（(A Phase II, Open-label, Single-center Platform Study）","sponsor":"Fudan University","enrolled":120,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05749588/","neighbours":{"cancer":[{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"camrelizumab","kind":"drug","name":"Camrelizumab","route":"/drugs/camrelizumab/"},{"id":"everolimus","kind":"drug","name":"Everolimus","route":"/drugs/everolimus/"},{"id":"tqb2102","kind":"drug","name":"TQB2102","route":"/drugs/tqb2102/"},{"id":"tqb2868","kind":"drug","name":"TQB2868","route":"/drugs/tqb2868/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}